RxDoctor Payments DataLook up a doctor →

Timothy Fignar, MD

Family Medicine · Enfield, CTNPI 1396766440

Payments from drug & device makers

$12,828in general payments, 2019–2025

Across 592 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Pfizer$819
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$12,66099%
  • Education$1681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,828 in reported general payments places this provider in the 90th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$50,566
Medicare patients
71
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$60,594
EliquisApixaban44$37,184
RybelsusSemaglutide21$36,136
Nurtec OdtRimegepant Sulfate19$32,357
Repatha SureclickEvolocumab36$30,137
FarxigaDapagliflozin Propanediol25$29,724
VraylarCariprazine Hcl14$29,538
XareltoRivaroxaban16$25,973
OxycontinOxycodone Hcl12$24,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$22,502
BelsomraSuvorexant36$21,358
JardianceEmpagliflozin23$18,651
TrulicityDulaglutide12$14,736
MovantikNaloxegol Oxalate24$12,052
LinzessLinaclotide11$9,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,516$96,73061 claims
PfizerEliquis, Nurtec Odt$819$69,54063 claims
AbbVieVraylar, Linzess$2,520$38,65925 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,215$34,98263 claims
AstraZenecaFarxiga$1,241$29,72425 claims
Johnson & JohnsonXarelto$60$25,97316 claims
MerckBelsomra$257$21,35836 claims
Boehringer IngelheimJardiance$263$18,65123 claims
Lilly USA, LLCTrulicity$1,140$14,73612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →